The Priority Review

Tag

Stream

353 stories · page 15 of 30

Stories

  1. Regulation

    Sales of Leqembi total 32.2 billion yen in third quarter 2026

    BioArctic AB reported preliminary global revenue for Leqembi of JPY 32.2 billion in the third quarter 2026, generating a royalty of SEK 203.8 million, up about 74 percent from the same period in 2025. The company disclosed the figures under the EU Market Abuse Regulation on October 28 2026.

  2. Regulation

    FDA issues priority review voucher for EMCITATE (tiratricol)

    The FDA announced that EMCITATE (tiratricol), approved September 28, 2026, manufactured by Rare Thyroid Therapeutics International AB, meets the criteria for a priority review voucher. The tablet is indicated for treating peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome).

  3. Regulation

    FDA releases draft guidance on electronic IDE submission template

    Comments on the draft guidance are due by December 28, 2026. The guidance targets sponsors filing IDE applications with the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research.

  4. Clinical trials

    Izalontamab brengitecan versus platinum chemotherapy in EGFR-mutated NSCLC

    In a phase 3 trial in China, 432 participants with EGFR-mutated advanced non-squamous NSCLC received either izalontamab brengitecan or platinum-based chemotherapy. Median BICR-assessed progression-free survival was 11·1 months with izalontamab brengitecan versus 5·7 months with chemotherapy (HR 0·40, 95% CI 0·31-0·51).

  5. Clinical trials

    Rudin et al. Report extended follow-up of tarlatamab in SCLC

    The authors reported that median overall survival was 13.6 months with tarlatamab versus 8.4 months with chemotherapy, with 12-month OS rates of 55.9% versus 39.0%. Grade ≥3 treatment-related adverse events decreased over time, with no serious events after 12 months.

  6. Policy

    Patrik Jonsson retires after 36 years; Ilya Yuffa named Lilly Global Markets president

    Patrik Jonsson has decided to retire at the end of 2026 after a 36-year career at Lilly. Ilya Yuffa will become executive vice president and president of Lilly Global Markets on Jan. 1, 2027, overseeing customer strategy worldwide.

  7. Clinical trials

    AbbVie submits BLA for etentamig to FDA for relapsed/refractory multiple myeloma

    AbbVie announced the submission of a Biologics License Application for etentamig, a second-generation BCMA x CD3 bispecific antibody, to the U.S. FDA for adults with relapsed or refractory multiple myeloma. The company cited Phase 3 CERVINO study results showing a 74.0% overall response rate versus 45.7% for investigator's choice and a 60% risk reduction in progression-free survival.

  8. Clinical trials

    Hanmi registers Phase 3 trial of HIP2602 in erectile dysfunction

    The study, led by Hanmi Pharmaceutical Company Limited, plans to enroll 225 participants and begin in October 2026. It is a multicenter, randomized, double-blind Phase III trial evaluating the efficacy and safety of HIP2602 in erectile dysfunction patients.

  9. Clinical trials

    AbbVie registers Phase 3 trial of upadacitinib in pediatric non-segmental vitiligo

    The study will enroll approximately 154 participants aged 6 to <12 years and is expected to start on January 28, 2027. It is to evaluate the efficacy, safety, and tolerability of upadacitinib over 48 weeks of treatment followed by 112 weeks of continued blinded therapy.

  10. Clinical trials

    Swedish Orphan Biovitrum registers Phase 3 trial of pegcetacoplan in kidney transplant recipients

    The study, titled PRESERVE, plans to enroll 30 participants and has a planned start date of January 21, 2027. It aims to assess the efficacy and safety of pegcetacoplan for preventing recurrent C3G or primary IC-MPGN, with a planned primary completion date of January 17, 2031.

  11. Clinical trials

    Amneal Pharmaceuticals registers Phase 3 trial of testosterone cypionate auto-injector

    The Phase 3 study, recruiting 190 participants, was first posted on ClinicalTrials.gov on October 27, 2026, with primary completion projected for March 31, 2027. It aims to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism.

  12. Clinical trials

    Bayer posts results of Phase 3 finerenone trial in CKD with type 1 diabetes

    The study, completed with 242 participants, compared finerenone plus standard of care to placebo in people with chronic kidney disease and type 1 diabetes. Results were first posted on ClinicalTrials.gov on October 27, 2026.